Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of a quadruple therapy (VX-222, telaprevir, peginterferon-alfa-2a, ribavirin) in adults with chronic hepatitis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)
• Telaprevir (telaprevir)
• VX-222 (VX-222)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Chronic Hepatitis C Virus | Phase 2 | Status: COMPLETED